R Naskar1, C K Vorwerk, E B Dreyer. 1. Scheie Eye Institute, Department of Ophthalmology, Veterans Administration, Philadelphia, USA.
Abstract
PURPOSE: Elevated levels of extracellular glutamate have been implicated in the pathophysiology of neuronal loss in both central nervous system and ophthalmic disorders, including glaucoma. This increase in glutamate may result from a failure of glutamate transporters, which are molecules that ordinarily regulate extracellular glutamate. Elevated glutamate levels can also lead to a perturbation in glutamate receptors. The hypothesis for the current study was that glutamate transporters and/or receptors are altered in human glaucoma. METHODS: Immunohistochemical analyses of human eyes with glaucoma and control eyes were performed to evaluate glutamate receptors and transporters. These molecules were also assayed in rat eyes injected with glial-derived neurotrophic factor (GDNF). RESULTS: Glaucomatous eyes had decreased levels of both the glutamate transporter, excitatory amino acid transporter (EAAT)-1, and the glutamate receptor subunit N-methyl-D-aspartate (NMDA)-R1. Eyes treated with GDNF had elevated levels of both EAAT1 and NMDAR1. CONCLUSIONS: The loss of EAAT1 in glaucoma may account for the elevated level of glutamate found in glaucomatous vitreous and lead to a compensatory downregulation of NMDAR1. Inasmuch as GDNF can increase levels of both EAAT1 and NMDAR1, it may be a useful therapeutic approach to restore homeostatic levels of these in glaucoma.
PURPOSE: Elevated levels of extracellular glutamate have been implicated in the pathophysiology of neuronal loss in both central nervous system and ophthalmic disorders, including glaucoma. This increase in glutamate may result from a failure of glutamate transporters, which are molecules that ordinarily regulate extracellular glutamate. Elevated glutamate levels can also lead to a perturbation in glutamate receptors. The hypothesis for the current study was that glutamate transporters and/or receptors are altered in humanglaucoma. METHODS: Immunohistochemical analyses of human eyes with glaucoma and control eyes were performed to evaluate glutamate receptors and transporters. These molecules were also assayed in rat eyes injected with glial-derived neurotrophic factor (GDNF). RESULTS:Glaucomatous eyes had decreased levels of both the glutamate transporter, excitatory amino acid transporter (EAAT)-1, and the glutamate receptor subunit N-methyl-D-aspartate (NMDA)-R1. Eyes treated with GDNF had elevated levels of both EAAT1 and NMDAR1. CONCLUSIONS: The loss of EAAT1 in glaucoma may account for the elevated level of glutamate found in glaucomatous vitreous and lead to a compensatory downregulation of NMDAR1. Inasmuch as GDNF can increase levels of both EAAT1 and NMDAR1, it may be a useful therapeutic approach to restore homeostatic levels of these in glaucoma.
Authors: Leon C Ho; Bo Wang; Ian P Conner; Yolandi van der Merwe; Richard A Bilonick; Seong-Gi Kim; Ed X Wu; Ian A Sigal; Gadi Wollstein; Joel S Schuman; Kevin C Chan Journal: Invest Ophthalmol Vis Sci Date: 2015-06 Impact factor: 4.799
Authors: Anne Katrine Toft-Kehler; Dorte Marie Skytt; Kristian Arild Poulsen; Charlotte Taul Brændstrup; Georgi Gegelashvili; Helle Waagepetersen; Miriam Kolko Journal: Neurochem Res Date: 2014-04-04 Impact factor: 3.996
Authors: Maria Ida Rizzo; Antonio Greco; Armando De Virgilio; Andrea Gallo; Luciano Taverniti; Massimo Fusconi; Michela Conte; Giulio Pagliuca; Rosaria Turchetta; Marco de Vincentiis Journal: Immunol Res Date: 2017-02 Impact factor: 2.829
Authors: Pratap Karki; Peter Hong; James Johnson; Edward Pajarillo; Deok-Soo Son; Michael Aschner; Eunsook Y Lee Journal: Mol Neurobiol Date: 2017-08-15 Impact factor: 5.590